Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺,不良综合征）或既往胃肠手术等均能响药物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工是进行系统深入的生物体内评价,解决药物透过血脑屏障和生物利用度等问题。